Press Releases
- Results from Active Biotech's Phase II/III ANYARA trial for the treatment of renal cell cancer January 28, 2013 08:30 (CET)
- Active Biotech to Present at the JP Morgan 31st Annual Healthcare Conference January 3, 2013 10:00 (CET)
- Laquinimod highlights from Teva Investor Day December 11 December 12, 2012 08:30 (CET)
- Teva Investor Meeting December 11 December 11, 2012 08:30 (CET)
- Active Biotech and Ipsen announce completion of recruitment of tasquinimod clinical phase III study in prostate cancer December 10, 2012 07:30 (CET)
- Active Biotech's election committee appointed November 15, 2012 08:30 (CET)
- Active Biotech AB Interim report January - September 2012 November 9, 2012 08:30 (CET)
- PHASE IIa LAQUINIMOD TRIAL RESULTS SHOW POSITIVE DATA FOR POTENTIAL USE IN ACTIVE CROHN'S DISEASE October 22, 2012 15:00 (CEST)
- Active Biotech's partner Ipsen initiates a proof-of-concept study with tasquinimod in additional cancer indications October 19, 2012 07:15 (CEST)
- Ipsen initiates a phase II "Switch maintenance" trial in metastatic castrate-resistant prostate cancer with tasquinimod October 3, 2012 18:30 (CEST)